Show
Sort by
-
- Journal Article
- open access
Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease
-
Metabolic response rates of epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma : updated EPCORE NHL-2 data
-
- Journal Article
- A1
- open access
Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression : results from the SORAYA study
-
Outcomes of childhood noninfant acute lymphoblastic leukemia with 11q23/KMT2A rearrangements in a modern therapy era : a retrospective international study
-
- Journal Article
- A1
- open access
Measurable residual disease and fusion partner independently predict survival and relapse risk in childhood KMT2A-rearranged acute myeloid leukemia : a study by the International Berlin-Frankfurt-Münster Study Group
-
Reply to Z.R. McCaw et al
-
- Journal Article
- A1
- open access
Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer : placebo-controlled randomized phase III ATALANTE/ENGOT-ov29 trial
-
- Journal Article
- A1
- open access
Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer : results from the innovaTV 205/GOG-3024/ENGOT-cx8 study
-
Short and medium-term outcomes of patients with solid cancer hospitalized with COVID-19 in Belgium according to cancer diagnosis and treatment characteristics
-
Subcutaneous epcoritamab plus R-DHAX/C in patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) eligible for autologous stem cell transplant (ASCT) : preliminary phase 1/2 results
-
Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy : CARTITUDE-2, cohort B
-
Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and >= 2 prior therapies : pivotal phase II expansion results
-
First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) plus R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL) : phase 1/2 data update
-
- Conference Paper
- C3
- open access
Predicting outcomes with circulating adrenergic neuroblastoma mRNAs in children with relapsed and refractory neuroblastoma : a BEACON-Neuroblastoma biomarker study
-
- Conference Paper
- C3
- open access
KEYNOTE-B79 phase 1b trial to evaluate the allogeneic CAR T-cells CYAD-101 and pembrolizumab in refractory metastatic colorectal cancer patients
-
- Journal Article
- A1
- open access
Integration of genomic biology into therapeutic strategies of gastric cancer peritoneal metastasis
-
- Journal Article
- A1
- open access
Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial
-
- Journal Article
- A1
- open access
Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer : analysis of STOMP and ORIOLE trials
-
- Journal Article
- A1
- open access
Combining Ixazomib with subcutaneous rituximab and dexamethasone in relapsed or refractory Waldenstrom's macroglobulinemia : final analysis of the phase I/II HOVON124/ECWM-R2 study
-
- Journal Article
- A1
- open access
The critical role of academic clinical trials in pediatric cancer drug approvals : design, conduct, and fit for purpose data for positive regulatory decisions
-
Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
-
A prospective phase I/IIa trial to evaluate the safety and efficacy of GTA002, an off-the-shelf, ex vivo-cultured allogeneic NK cell preparation in patients with acute myeloid leukemia in complete morphological remission who have measurable residual disease
-
- Conference Paper
- C3
- open access
Intraperitoneal aerosolized nanoparticle albumin based paclitaxel (NAB-PTX) for irresectable peritoneal metastases : a first in human phase I study
-
Retrospective analysis of mpMRI to predict complete pathologic response after neo-adjuvant chemotherapy for muscle invasive bladder cancer
-
- Journal Article
- A1
- open access
Frequency and prognostic impact of ALK amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) high-risk neuroblastoma trial (HR-NBL1)
-
- Journal Article
- A1
- open access
Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma : a phase I trial
-
Elective cancer surgery in COVID-19-free surgical pathways during the SARS-CoV-2 pandemic : an international, multicenter, comparative cohort study
-
- Journal Article
- A1
- open access
Influence of surgical excision on the survival of patients with stage 4 high-risk neuroblastoma : a report from the HR-NBL1/SIOPEN study
-
Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families
-
Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).
-
Uncovering the immune-modulating role of anti-RANKL therapy for cervical cancer : preliminary results
-
- Journal Article
- A1
- open access
Has the PROPHECY of AR-V7 been fulfilled?
-
Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial
-
- Journal Article
- A1
- open access
AUGMENT : a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma
-
Randomized phase I trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma : clinical and translational results
-
Efficacy and safety of lanreotide 120 mg in the treatment of clinical symptoms associated with inoperable malignant intestinal obstruction (IMIO) : results from a phase II multicenter study.
-
Preoperative chemosensitivity testing as predictor of treatment benefit in adjuvant stage III colon cancer : preliminary analysis of the PePiTA study
-
Treatment of ovarian cancer with intraperitoneal platinum : heating up the debate
-
Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma : long-term results of the PRIMA study
-
Efficacy and time to next treatment following lenalidomide/rituximab (R-2) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT)
-
Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL) : final analysis of the phase 3 COMPLEMENT 1 trial.
-
Cost-effectiveness of a two-gene urine biomarker assay in MRI strategies for the initial detection of prostate cancer
-
Clinical utility study of confirms mdx for prostate cancer in a community urology practice
-
Validation of a two-gene mRNA urine test for detection of high-grade prostate cancer in German men
-
Phase Ib study of talimogene laherparepvec (T-VEC) injection into liver metastases (LMs) in combination with intravenous (IV) atezolizumab in patients (pts) with metastatic triple negative breast cancer (TNBC) or colorectal cancer (CRC).
-
A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors
-
Effects of molecular tumor board and different NGS panels implementation for the treatment of patients with cancer
-
High levels of cell-free DNA (cfDNA) at baseline (BL) and increase of at least one mutation at day 14 (D14) as independent prognostic biomarkers for patients (pts) with advanced colorectal cancer (aCRC) under regorafenib
-
- Journal Article
- A1
- open access
Reply to J.-E. Bibault et al, B. Tombal, and C. Cattrini et al
-
Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence : a prospective, randomized, multicenter phase II trial
-
Randomized, open-label, phase 2/3 study of daratumumab (DARA) with or without JNJ-63723283, an anti-PD-1 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM)
-
Prognostic significance of number versus location of positive mesenteric nodes in node positive colon cancer
-
Role of ofatumumab (OFA) maintenance treatment in relapsed chronic lymphocytic leukemia (CLL): Final analysis of PROLONG study.
-
Baseline cell-free DNA (cfDNA) and metabolic tumor volume (MTV) independently predict outcome in metastatic chemorefractory colorectal cancer (mCRC)
-
Immune cell profiling of melanoma metastases from patients treated with TriMixDC-MEL dendritic cell therapy in combination with ipilimumab
-
A NKG2D-based CAR-T therapy in a multinational phase I dose escalation and expansion study targeting multiple solid and hematologic tumor types
-
Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)
-
Distrust in the end-of-life care provided to a parent and long-term negative outcomes among bereaved adolescents : a population-based survey study
-
Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores
-
Phase I study of mTORC1/2 inhibitor BI 860585 as single agent or with exemestane or paclitaxel in patients with advanced solid tumors
-
Clinical response observed in a phase I study in T cell lymphoma patients treated with anti-CD70 SIMPLE antibody ARGX-110
-
Ability of an epigenetic assay to identify anterior prostate tumors based on a negative 12-core biopsy
-
Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial
-
Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial
-
Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma
-
Combined DNA-methylation intensity and clinical risk score to stratify patients for high-grade disease
-
Childhood acute lymphoblastic leukemia : progress through collaboration
-
Evaluation of the value of serum glycomics (GlycoCirrhoTest) for risk prediction of hepatocellular carcinoma in compensated cirrhosis
-
Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP : first results of the EURAMOS-1 good respons randomized controlled trial
-
Acute toxicity and quality of life after dose-intensified salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy : first results of the randomized trial SAKK 09/10
-
Acute toxicity and early quality of life after dose intensified salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: first results of the randomized trial SAKK 09/10
-
Clinical impact of additional cytogenetic aberrations, cKIT and RAS mutations, and treatment elements in pediatric t(8;21)-AML : results from an international retrospective study by the International Berlin-Frankfurt-Münster study group
-
Collaborative efforts driving progress in pediatric acute myeloid leukemia
-
Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20⁺ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study
-
Evaluation of abiraterone acetate post-docetaxel in the Belgian compassionate use program
-
Identification of a predictive signature based on immunohistochemical (IHC), RNA-seq and epigenetic profiling of melanoma metastases for response to ipilimumab-based immunotherapy
-
Effect of sunitinib treatment on mutations and methylation in metastatic renal cancer
-
Toxicities and doses of chemotherapy drugs in hyperthermic intraperitoneal chemotherapy (HIPEC)
-
A first-in-class, first-in-human phase I study of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intravenously in patients with metastatic epithelial tumors
-
2013 Update of the American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: impact on immunohistochemistry-negative breast cancers
-
Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study
-
Regorafenib assessment guided by metabolic imaging in refractory advanced colorectal cancer (aCRC) : REGARD-C study
-
Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial
-
Emergence of new ALK mutations at relapse of neuroblastoma
-
Epigenetic profiling of prostate cancer tissue to identify men with high-risk disease
-
A phase I first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in immune escape and tumor growth in patients with solid and hematologic malignancies
-
Nomograms to predict prognosis in pseudomyxoma peritonei: a Peritoneal Surface Oncology Group International (PSOGI) multicenter study
-
DUO: a phase 3 trial of the PL3K-delta,gamma inhibitor IPI-145 versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphorytic lymphoma
-
Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) for relapsed or refractory multiple myeloma (RRMM): overall survival (OS) results of MM-003 after adjustment for Res crossover
-
Durable disease control with sunitinib and everolimus in well-differentiated neuroendocrine tumors of the pancreas with a high ki67 index
-
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab
-
Type I and II endometrial cancers : have they different risk factors?
-
Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium: a Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique study
-
Assessment of the quality of the pathological evaluation of total mesorectal excision specimens : differences in evaluation between local pathologists and a review committee in the context of an improvement project
-
Trends in end-of-life decision making in patients with and without cancer
-
CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer
-
Prediction of risk for prostate cancer in histopathologically negative biopsies by multigene epigenetic assay
-
Association of DNA promoter hypermethylation of decoy receptor 1 (DCR1) with poor response to irinotecan in metastatic colorectal cancer
-
Serum mesothelin for diagnosing malignant pleural mesothelioma : an individual patient data meta-analysis
-
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study